Association between cancer history and second-generation drug-eluting stent thrombosis: insights from the REAL-ST registry

Table 4 Clinical Events throughout the Entire Follow-up Period

	ST (n = 253)				Controls (n = 1012)
	Patients with events (Cumulative 4-year incidence)		HR (95% CI)	p-value	Patients with events (Cumulative 4-year incidence)		HR (95% CI)	p-value
	Cancer (n = 31)	Non-cancer (n = 222)	HR (95% CI)	p-value	Cancer (n = 86)	Non-cancer (n = 926)	HR (95% CI)	p-value
All-cause death	13 (62.7%)	66 (32.2%)	1.93 (1.06–3.51)	0.031	19 (24.0%)	100 (12.6%)	1.93 (1.09–3.40)	0.023
Cardiac death	9 (30.0%)	47 (22.1%)	1.63 (0.80–3.34)	0.18	4 (5.1%)	18 (2.3%)	2.40 (0.69–8.37)	0.17
Non-cardiac death	4 (46.7%)	15 (8.9%)	3.05 (1.01–9.21)	0.048	14 (19.8%)	66 (8.7%)	2.24 (1.17–4.29)	0.015
Non-fatal MI	3 (12.5%)	15 (8.6%)	1.89 (0.54–6.55)	0.32	1 (1.4%)	10 (1.2%)	1.13 (0.14–8.84)	0.91
TLR	4 (34.3%)	42 (27.4%)	0.99 (0.36–2.78)	0.99	8 (13.1%)	74 (7.8%)	1.13 (0.49–2.61)	0.78
MACE	15 (67.9%)	77 (36.0%)	1.96 (1.12–3.41)	0.018	23 (28.4%)	123 (14.9%)	1.97 (1.19–3.25)	0.008
Recurrent ST	2 (7.6%)	11 (5.5%)	1.41 (0.31–6.36)	0.66	-	-	-	NA
Bleeding	1 (12.5%)	4 (2.6%)	2.58 (0.29–23.3)	0.40	6 (6.1%)	24 (2.5%)	2.13 (0.79–5.78)	0.14

Values are n (%), unless otherwise indicated. The number of patients with an event was counted until the end of follow up. Cumulative 4-year incidence was estimated by the Kaplan–Meier method. HRs with 95% CIs of the cancer group relative to the non-cancer group for the outcome measures were estimated throughout the entire follow-up period by the Cox proportional hazards models
CI confidence interval, HR hazard ratio, MACE major adverse cardiovascular events, MI myocardial infarction, ST stent thrombosis, TLR target lesion revascularization

ISSN: 1477-9560